The drug major has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan nasal spray, 20 mg from the United States Food and Drug Administration (USFDA).
The product is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline s Imitrex nasal spray. Imitrex is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults.
According to IQVIA (IMS Health), Imitrex nasal spray 20 mg and its generic equivalents had US sales of approximately $53.3 million for the 12-month period ending December 2020.
Separately, Cipla announced that its subsidiary, Cipla Gulf FZ LCC, is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.
Washington County adapts to life under moderate risk March 02 2021
Restaurants, fitness centers and more are allowed to up their capacity this week as COVID-19 cases continue to fall.
The coronavirus picture keeps improving in Washington County, where businesses are now being allowed to relax health and safety protocols a little further still.
Gov. Kate Brown declared Washington County, as well as neighboring Clackamas County, to be at moderate risk of COVID-19 community spread as of Friday, Feb. 26.
The move down from high risk came just two weeks after the most stringent restrictions were rolled back, following about two months during which Washington County was considered to be at an extreme risk level.
The US stocks climbed up on Monday, 01 March 2021, with the S&P 500, the Dow index, and the broader Nasdaq all to settling higher, as encouraging updates on COVID-19 vaccines and fiscal stimulus bolstered bets over a swift economic recovery.
At the close of trade, the Dow Jones Industrial Average index advanced 603.14 points, or 1.95%, to 31,535.51. The S&P500 index dropped 90.67 points, or 2.38%, to 3,901.82. The tech-heavy Nasdaq Composite Index added 396.48 points, or 3.01%, to 13,588.83.
Major indices leapt at the open and remained in positive territory the entire day, as investors cheered the emergency use approval of Johnson & Johnson s single-dose Covid-19 vaccine by US regulators over the weekend, giving the nation a third shot to battle the world s worst outbreak.
Bajaj Healthcare rose 3.80% to Rs 495 after the company received consent from Maharashtra Control Board (MPCB) to resume its operations at Tarapur unit in Maharashtra.
The MPCB had issued a notice on 14 January 2021 to the company directing the closure of operations at its Tarapur unit for alleged violation of the provisions of Water (Prevention and Control of Pollution) Act 1974, Air (Prevention and Control Pollution) Act 1981 and the Rules made thereunder.
MPCB vide its letter dated 1 March 2021 gave its consent to the company for restarting manufacturing activities at its unit situated at MIDC Tarapur.
Bajaj Healthcare is a leading manufacturer of APIs, intermediates and formulations. The company s net profit surged to Rs 326.1% to Rs 26.42 crore on a 79.6% to Rs 178.33 crore in Q3 FY21 over Q3 FY20.
At meeting held on 27 February 2021The Board of Aurobindo Pharma at its meeting held on 27 February 2021 has approved the following -
1. Transfer of all equity shares held in Lyfius Pharma, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics, another wholly owned subsidiary of the Company.
2. Transfer of all equity shares held in Qule Pharma, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics, another wholly owned subsidiary of the Company.
3. Transfer of business undertaking comprised in Unit-10, on a going concern basis, to APL Healthcare, a wholly owned subsidiary of the Company.
Powered by Capital Market - Live News